<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115307</article-id><article-id pub-id-type="publisher-id">ACM-42349</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_26838059.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童可逆性胼胝体压部病变综合征的文献回顾
  Literature Review of Reversible Splenial Lesion Syndrome in Children
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>兰昕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>程</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>重庆医科大学附属儿童医院神经内科，重庆；国家儿童健康与疾病临床医学研究中心，重庆；儿童发育疾病研究教育部重点实验室，重庆；儿科学重庆市重点实验室，重庆</addr-line></aff><aff id="aff2"><addr-line>重庆医科大学附属儿童医院神经内科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2147</fpage><lpage>2154</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：研究近年报道的儿童可逆性胼胝体压部病变综合征(RESLES)的临床特征，为临床医生提供诊疗经验。方法：通过PubMed对2016年1月至2020年10之间关于RESLES的报道进行检索，并筛选出儿童RESLES病例，对其临床表现、实验室数据、影像学检查及治疗预后进行归纳总结。结果：从纳入文献中总结了27个儿童RESLES的病例，66.7%病例报道在亚洲(18/27)，特别是日本(9/27)。年龄在生后7 h至14岁之间变化，女性至男性比例为1:1.7，主要原因是病毒或细菌感染，发烧和惊厥发作是最常见的临床表现，92.6%患者完全恢复(25/27)，其余包括未报告预后1例，有神经系统后遗症1例。结论：儿童RESLES的特征性影像表现是以胼胝体压部出现扩散受限的可逆性改变，伴或不伴脑白质和胼胝体其他部位病变，是一种临床预后相对良好的临床–影像综合征，其临床表现及实验室检查无特异性，治疗方案尚未达成统一共识。
   Objective: We reviewed the literature on children with reversible splenial lesion syndrome (RESLES) in order to describe the characteristics of RESLES in children and to provide experiences for clinician. Method: We performed literature search from PubMed to identify the children with RESLES reports from January 2016 to October 2020. And then we summarized the clinicoradiological features of RESLES in children. Result: Twenty-seven child-onset RESLES cases were reviewed from available literature including the case we have. 66.7% of the cases (18/27) were reported in Asia, especially in Japan (9/27). Ages varied between 7 h and 14 years old with a 1:1.7 male-to-female ratio. The major cause was infection by virus or bacteria. Fever and seizure were the most common clinical manifestation, 92.6% patients recovered completely (25/27), and the prognosis of one case was not reported, while the other had residual neurologic sequelae. Conclusion: The radiological features of Child-onset RESLES is reversible splenial lesion and restricted diffusion, with or without white matter lesion and other involved lesions in the corpus callosum. The prognosis is often well, while the clinical findings are not specific and there is no consensus on the treatment plan.
 
</p></abstract><kwd-group><kwd>可逆性胼胝体压部病变综合征，临床特征，儿童，文献回顾, Reversible Splenial Lesion Syndrome</kwd><kwd> Clinical Features</kwd><kwd> Children</kwd><kwd> Literature Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：研究近年报道的儿童可逆性胼胝体压部病变综合征(RESLES)的临床特征，为临床医生提供诊疗经验。方法：通过PubMed对2016年1月至2020年10之间关于RESLES的报道进行检索，并筛选出儿童RESLES病例，对其临床表现、实验室数据、影像学检查及治疗预后进行归纳总结。结果：从纳入文献中总结了27个儿童RESLES的病例，66.7%病例报道在亚洲(18/27)，特别是日本(9/27)。年龄在生后7 h至14岁之间变化，女性至男性比例为1:1.7，主要原因是病毒或细菌感染，发烧和惊厥发作是最常见的临床表现，92.6%患者完全恢复(25/27)，其余包括未报告预后1例，有神经系统后遗症1例。结论：儿童RESLES的特征性影像表现是以胼胝体压部出现扩散受限的可逆性改变，伴或不伴脑白质和胼胝体其他部位病变，是一种临床预后相对良好的临床–影像综合征，其临床表现及实验室检查无特异性，治疗方案尚未达成统一共识。</p></sec><sec id="s2"><title>关键词</title><p>可逆性胼胝体压部病变综合征，临床特征，儿童，文献回顾</p></sec><sec id="s3"><title>Literature Review of Reversible Splenial Lesion Syndrome in Children</title><p>Lanxin Liu<sup>1</sup>, Min Cheng<sup>1,2,3,4*</sup></p><p><sup>1</sup>Department of Neurological in Children’s Hospital of Chongqing Medical University, Chongqing</p><p><sup>2</sup>National Clinical Research Center for Child Health and Disorders, Chongqing</p><p><sup>3</sup>Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing</p><p><sup>4</sup>Chongqing Key Laboratory of Pediatrics, Chongqing</p><p><img src="//html.hanspub.org/file/16-1572251x4_hanspub.png" /></p><p>Received: Apr. 17<sup>th</sup>, 2021; accepted: May 2<sup>nd</sup>, 2021; published: May 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/16-1572251x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: We reviewed the literature on children with reversible splenial lesion syndrome (RESLES) in order to describe the characteristics of RESLES in children and to provide experiences for clinician. Method: We performed literature search from PubMed to identify the children with RESLES reports from January 2016 to October 2020. And then we summarized the clinicoradiological features of RESLES in children. Result: Twenty-seven child-onset RESLES cases were reviewed from available literature including the case we have. 66.7% of the cases (18/27) were reported in Asia, especially in Japan (9/27). Ages varied between 7 h and 14 years old with a 1:1.7 male-to-female ratio. The major cause was infection by virus or bacteria. Fever and seizure were the most common clinical manifestation, 92.6% patients recovered completely (25/27), and the prognosis of one case was not reported, while the other had residual neurologic sequelae. Conclusion: The radiological features of Child-onset RESLES is reversible splenial lesion and restricted diffusion, with or without white matter lesion and other involved lesions in the corpus callosum. The prognosis is often well, while the clinical findings are not specific and there is no consensus on the treatment plan.</p><p>Keywords:Reversible Splenial Lesion Syndrome, Clinical Features, Children, Literature Review</p><disp-formula id="hanspub.42349-formula15"><graphic xlink:href="//html.hanspub.org/file/16-1572251x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/16-1572251x8_hanspub.png" /> <img src="//html.hanspub.org/file/16-1572251x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>Kim等人 [<xref ref-type="bibr" rid="hanspub.42349-ref1">1</xref>] 在1999年首次报道了可逆性胼胝体压部病变综合征(RESLES)，在口服抗癫痫药物患者的磁共振(MRI)中发现胼胝体压部(SCC)存在可逆性卵圆形病变，其在T1加权序列(T1WI)上呈低信号，在T2加权序列(T2WI)上呈高信号，且使用增强剂时未发现增强效应。Tada等人 [<xref ref-type="bibr" rid="hanspub.42349-ref2">2</xref>] 在2004年提出将MRI上存在可逆的孤立性胼胝体压部病变，临床上具有相对较轻中枢神经系统表现，并且能在1月内完全康复的一类疾病称为伴胼胝体压部病变的临床症状轻微的脑炎/脑病(MERS)。后来Garcia等人 [<xref ref-type="bibr" rid="hanspub.42349-ref3">3</xref>] 在2011年通过回顾总结既往文献报道提出了可逆性胼胝体压部病变综合征(RESLES)这一概念，并制定了RESLES的临床诊断标准：1) MRI上可见病变累及胼胝体压部；2) 随访过程中病变明显改善或消失；3) 需除外急性播散性脑病及其他常见脱髓鞘疾病，而目前则认为MERS是RESLES疾病谱中的一种 [<xref ref-type="bibr" rid="hanspub.42349-ref4">4</xref>]。RESLES的病因复杂多样，其发病机制尚不清楚，国内外对RESLES的报道以个案居多。RESLES在儿童及成人中均有报道，目前尚未达成统一的临床诊疗共识。由于RESLES预后一般良好，极少有后遗症，所以在临床上尽早识别本病能够避免不必要的侵入性操作及过度诊疗。</p></sec><sec id="s6"><title>2. 研究方法</title><p>为了更好了解儿童RESLES的临床特点，通过PubMed对2016年1月至2020年10月间关于RESLES的报道进行检索，使用以下术语“reversible splenial lesion”“reversible corpus callosum lesion”“mild encephalitis/encephalopathy with reversible splenial lesion”“RESLES”来检索所有英文的相关文献报道，不包括非英语文献报道、成人RESLES文献报道以及无法获得全文或详细数据的文献报道等，见图1。通过文献阅读，对以下信息进行提取整理：第一作者姓氏、研究所在的地区、患儿的年龄、性别、神经系统(CNS)症状、神经系统体格检查、病因、辅助检查、治疗以及结果。</p><p>图1. 文献筛选的流程图</p></sec><sec id="s7"><title>3. 结果</title><p>27例儿童RESLES中，9例来自日本，7例来自中国，1例来自朝鲜，1例来自缅甸，4例来自意大利，2例来自美国，1例来自法国，1例来自拉脱维亚，1例来自德国。从地理位置来看，病例主要分布在亚洲(66.7%，18/27)，特别是日本(33.3%，9/27)和中国(25.9%，7/27)。发病年龄从生后7 h至14岁不等，平均发病年龄为6.7岁(6.7 &#177; 5岁)，其中女性17例(63.0%，17/27)，男性10例(37%，10/27)，男女比例为1:1.7。</p><p>发热是最常见的前驱症状(74.1%，20/27)，其他前驱症状还包括消化道症状(呕吐、腹泻、腹痛)、咳嗽、呻吟、喂养困难及皮疹等。仅1例在起病前2周有明确前驱感染病史，表现为食欲不振，疲倦，头痛，但不伴发热(病例23)。儿童常见的神经系统表现为意识障碍(55.6%，15/27)、惊厥(37.0%，10/27)、头痛(22.2%，6/27)、精神行为异常(18.5%，5/27)。其他较少见的神经系统症状还包括：头晕、共济失调、幻觉、语言障碍(构音障碍、失语等)、急性尿潴留、震颤、不自主运动(咀嚼、吞咽等)、眼震及眼肌麻痹、畏光/声以及类似卒中样发作等，见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic data of 27 children with RESLE</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >作者</th><th align="center" valign="middle" >地域</th><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >性别</th><th align="center" valign="middle" >年龄</th><th align="center" valign="middle" >临床表现(前驱症状；神经系统症状)</th><th align="center" valign="middle" >神经系统查体</th><th align="center" valign="middle" >病原学</th></tr></thead><tr><td align="center" valign="middle" >J. Lin</td><td align="center" valign="middle" >美国</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >13y</td><td align="center" valign="middle" >发热、呕吐、腹泻、咳嗽；头晕和步态不稳、尿潴留、间歇性幻听</td><td align="center" valign="middle" >肌张力降低、深肌腱反射减弱，踝反射消失</td><td align="center" valign="middle" >COVID-19 CSF IgM(+)、 血清PCR(+)</td></tr><tr><td align="center" valign="middle" >Enrico Masiello</td><td align="center" valign="middle" >意大利</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >4y</td><td align="center" valign="middle" >发热、腹泻；吞咽困难、构音障碍</td><td align="center" valign="middle" >GCS 12，肌张力降低</td><td align="center" valign="middle" >埃可病毒 血清IgM(+)、 大便培养(+)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >Antonio Gatto</th><th align="center" valign="middle" >意大利</th><th align="center" valign="middle" >3</th><th align="center" valign="middle" >F</th><th align="center" valign="middle" >5y</th><th align="center" valign="middle" >发热、呕吐；乏力、失语、共济失调</th><th align="center" valign="middle" >未报告</th><th align="center" valign="middle" >H1N1 咽拭子PCR(+)</th></tr></thead><tr><td align="center" valign="middle" >Valentin Oger</td><td align="center" valign="middle" >法国</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >10y</td><td align="center" valign="middle" >发热、呕吐；头痛、意识障碍、心律失常、眼震、步态异常</td><td align="center" valign="middle" >肌张力障碍，眼球运动异常，颊舌运动障碍</td><td align="center" valign="middle" >抗GFAP抗体 CSF(+)</td></tr><tr><td align="center" valign="middle" >George IMATAKA</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >6y</td><td align="center" valign="middle" >发热；惊厥，意识障碍(昏迷)</td><td align="center" valign="middle" >未报告</td><td align="center" valign="middle" >流感病毒A 血清Ag(+)</td></tr><tr><td align="center" valign="middle" >EmmanDabaja</td><td align="center" valign="middle" >美国</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >10y</td><td align="center" valign="middle" >发热、皮疹；头痛、幻觉</td><td align="center" valign="middle" >未见异常</td><td align="center" valign="middle" >立克次体 血清IgG 1:256、 IgM &lt; 1:64</td></tr><tr><td align="center" valign="middle" >GuntaLaizane</td><td align="center" valign="middle" >拉脱维亚</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >2y</td><td align="center" valign="middle" >发热、腹泻、呕吐；惊厥、意识障碍</td><td align="center" valign="middle" >未见异常</td><td align="center" valign="middle" >轮状病毒 大便Ag(+)</td></tr><tr><td align="center" valign="middle" >GEORGE IMA TAKA</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >9y</td><td align="center" valign="middle" >发热、腹痛；语言障碍、意识障碍</td><td align="center" valign="middle" >未报告</td><td align="center" valign="middle" >-(抗生素使用导致假阴性?)</td></tr><tr><td align="center" valign="middle" >Jialu Xu</td><td align="center" valign="middle" >中国</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >2.5y</td><td align="center" valign="middle" >发热、呕吐；惊厥、意识障碍(昏迷)</td><td align="center" valign="middle" >GCS 5</td><td align="center" valign="middle" >李斯特菌 CSF培养(+)</td></tr><tr><td align="center" valign="middle" >AsamiShimbo</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >10y</td><td align="center" valign="middle" >发热；颈部僵硬、行为异常</td><td align="center" valign="middle" >颈强直</td><td align="center" valign="middle" >李斯特菌 CSF培养(+)</td></tr><tr><td align="center" valign="middle" >Jung Sook Yeom</td><td align="center" valign="middle" >朝鲜</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >12y</td><td align="center" valign="middle" >发热；排尿困难、精神错乱、言语异常、震颤、共济失调</td><td align="center" valign="middle" >未报告</td><td align="center" valign="middle" >大肠埃希菌 尿培养(+)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >意大利</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >22m</td><td align="center" valign="middle" >发热；惊厥</td><td align="center" valign="middle" >嗜睡</td><td align="center" valign="middle" >CMV 血清IgM(+)</td></tr><tr><td align="center" valign="middle" >Norishi Ueda</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >14y</td><td align="center" valign="middle" >发热、咳嗽；言语异常、幻觉，行为异常</td><td align="center" valign="middle" >GCS 8</td><td align="center" valign="middle" >肺炎支原体 血清IgM(+)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >8y</td><td align="center" valign="middle" >发热、咳嗽、头痛、呕吐、腹泻；意识障碍(嗜睡)、惊厥、共济失调、震颤</td><td align="center" valign="middle" >GCS 8</td><td align="center" valign="middle" >肺炎支原体 血清IgM(+)</td></tr><tr><td align="center" valign="middle" >Dan SUN</td><td align="center" valign="middle" >中国</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >2d</td><td align="center" valign="middle" >反应差、惊厥</td><td align="center" valign="middle" >反应低下</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >3d</td><td align="center" valign="middle" >反应差、喂养困难、惊厥</td><td align="center" valign="middle" >肌张力增高，原始反射减弱</td><td align="center" valign="middle" >口腔真菌感染</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >12d</td><td align="center" valign="middle" >惊厥</td><td align="center" valign="middle" >肌张力增高，原始反射减弱</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >3d</td><td align="center" valign="middle" >惊厥</td><td align="center" valign="middle" >肌张力增高，原始反射减弱</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >7h</td><td align="center" valign="middle" >呻吟、不安</td><td align="center" valign="middle" >未见异常</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Ai Hosoda</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >3y1m</td><td align="center" valign="middle" >发热；惊厥</td><td align="center" valign="middle" >未报告</td><td align="center" valign="middle" >B族链球菌 血培养(+)</td></tr><tr><td align="center" valign="middle" >Choong Yi Fong</td><td align="center" valign="middle" >缅甸</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >12y</td><td align="center" valign="middle" >发热伴寒战；精神错乱、双眼肌麻痹</td><td align="center" valign="middle" >GCS7-13，双侧眼肌麻痹</td><td align="center" valign="middle" >登革病毒 血清IgM(+) PCR(+);CSF PCR(+)</td></tr><tr><td align="center" valign="middle" >Hiroshi Yamaguchi</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >3y</td><td align="center" valign="middle" >发热、腹痛；易怒、步态异常、精神错乱</td><td align="center" valign="middle" >GCS 12</td><td align="center" valign="middle" >EB病毒 IgM(+)、 PCR1.0*10<sup>6</sup> copies/mg</td></tr><tr><td align="center" valign="middle" >Kai Dong</td><td align="center" valign="middle" >中国</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >12y</td><td align="center" valign="middle" >前驱感染(食欲不振，疲倦，头痛)；右上肢三次发作无力、构音障碍、呕吐</td><td align="center" valign="middle" >未报告</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><table-wrap id="1_3"><table><tbody><thead><tr><th align="center" valign="middle" >Mitsuru Ikeno</th><th align="center" valign="middle" >日本</th><th align="center" valign="middle" >24</th><th align="center" valign="middle" >F</th><th align="center" valign="middle" >14Y</th><th align="center" valign="middle" >发热；头痛、意识障碍</th><th align="center" valign="middle" >GCS 14</th><th align="center" valign="middle" >-</th></tr></thead><tr><td align="center" valign="middle" >GulhadiyeAvcu</td><td align="center" valign="middle" >德国</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >10y</td><td align="center" valign="middle" >发热、呕吐；不自主运动(吞咽、咀嚼)</td><td align="center" valign="middle" >GCS 10，BP 170/100 mmHg</td><td align="center" valign="middle" >肺炎链球菌 血培养(+)</td></tr><tr><td align="center" valign="middle" >Yuki Kasuga</td><td align="center" valign="middle" >日本</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5y</td><td align="center" valign="middle" >发热、呕吐、腹痛；行为异常、意识障碍</td><td align="center" valign="middle" >GCS 13</td><td align="center" valign="middle" >大肠埃希菌 血/尿培养(+)</td></tr><tr><td align="center" valign="middle" >Laura Cursi</td><td align="center" valign="middle" >意大利</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >14y</td><td align="center" valign="middle" >发热；头痛、意识障碍、畏光和畏声、眼球运动疼痛、呼吸暂停、尿便潴留、精神运动危象(心动过速、气促喘息、头晕乏力)</td><td align="center" valign="middle" >易激惹</td><td align="center" valign="middle" >人疱疹病毒-6 血清PCR(+)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 27例儿童RESLES的一般资料</p><p>F，女性；M，男性；y，年；CSF，脑脊液；GCS，哥斯拉昏迷评分。</p><p>27例患儿完善了病原学检查，19例病原学阳性(70.4%，19/27)，7例病原不明(25.9%，7/27)，其中有1例与自身免疫性疾病相关(病例5为抗GFAP抗体阳性)。感染以病毒为主(47.4%，9/19)，其中包括2例流感病毒、1例COVID-19、1例埃可病毒、1例轮状病毒、1例巨细胞病毒、1例EB病毒、1例登革热病毒、1例人疱疹病毒-6。其次是细菌感染(31.5%，6/19)，其中包括2例李斯特菌、2例大肠埃希菌、1例肺炎链球菌、1例B族链球菌。另外，有特殊病原体感染4例(21.1%)，其中包括2例肺炎支原体、1例立克次体、1例真菌。21例报告了血钠浓度，平均浓度127.6 mmol/L (127.6 &#177; 5.6 mmol/L)，其中13例有低钠血症(61.9%，13/21)。炎症指标：WBC (10.7 &#177; 7.7 &#215; 10<sup>9</sup>/L)、CRP 75.5 &#177; 59.7 (mg/L)。23例报告了外周白细胞计数(WBC)，其平均值为10.7 (10.7 &#177; 7.7 &#215; 10<sup>9</sup>/L)，其中有5例WBC升高(21.7%，5/23)；19例报告了C反应蛋白(CRP)数值，平均值75.5 mg/L (75.5 &#177; 59.7 mg/L)，见表1、表2。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Auxiliary examination data and prognosis of 27 children with RESLE</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >病例</th><th align="center" valign="middle" >WBC*10^9/L</th><th align="center" valign="middle" >CRP (mg/L)</th><th align="center" valign="middle" >Na+ (mmol/L)</th><th align="center" valign="middle" >CSF-细胞数</th><th align="center" valign="middle" >首次MRI</th><th align="center" valign="middle" >病变消失的时间间隔</th><th align="center" valign="middle" >EEG</th><th align="center" valign="middle" >治疗</th><th align="center" valign="middle" >预后</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >9.78</td><td align="center" valign="middle" >100.9</td><td align="center" valign="middle" >128</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >2.5 m</td><td align="center" valign="middle" >弥漫性慢波，无痫性放电</td><td align="center" valign="middle" >IVIG</td><td align="center" valign="middle" >NR</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6.79</td><td align="center" valign="middle" >130</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >15 d</td><td align="center" valign="middle" >双颞区高压慢波，无阵发性放电活动</td><td align="center" valign="middle" >头孢曲松、阿昔洛韦、甲强龙/改泼尼松</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >N</td><td align="center" valign="middle" >29.4</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >II型，累及齿状核、小脑白质</td><td align="center" valign="middle" >21 d</td><td align="center" valign="middle" >后头部区域棘波</td><td align="center" valign="middle" >阿昔洛韦/奥司他韦、头孢曲松、左乙拉西坦</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >124</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >弥漫性慢波</td><td align="center" valign="middle" >IVIG</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >甲强龙，IVIG</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >II型，累及左侧额叶深层和皮质下白质</td><td align="center" valign="middle" >8 w</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >阿昔洛韦；头孢曲松 + 多西环素</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >N</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >2 m</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >苯巴比妥</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >3.2</td><td align="center" valign="middle" >73.9</td><td align="center" valign="middle" >130</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >II型，累及两侧白质</td><td align="center" valign="middle" >2 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >IVIG，类固醇激素</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >21.09</td><td align="center" valign="middle" >180</td><td align="center" valign="middle" >118</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >帕尼培南 + 万古霉素</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >16.1</td><td align="center" valign="middle" >43.2</td><td align="center" valign="middle" >126</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >11 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >美罗培南、头孢噻肟，地塞米松</td><td align="center" valign="middle" >CR</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >11</th><th align="center" valign="middle" >18.34</th><th align="center" valign="middle" >81</th><th align="center" valign="middle" >136</th><th align="center" valign="middle" >正常</th><th align="center" valign="middle" >II型，累及胼胝体其他部位及两侧对称深部白质</th><th align="center" valign="middle" >18 d</th><th align="center" valign="middle" >NE</th><th align="center" valign="middle" >头孢噻肟 + 妥布霉素，哌拉西林他唑巴坦 + 阿米卡星</th><th align="center" valign="middle" >CR</th></tr></thead><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >49.2</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >14 d</td><td align="center" valign="middle" >左额叶起源泛化的痫样放电，左半球异常的弥漫性高电压电活动</td><td align="center" valign="middle" >左乙拉西坦 + 静脉抗病毒(具体未说明)</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >7.68</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >134</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >4 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >米诺环素 + 地塞米松 + 阿昔洛韦</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >6.47</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >II型，累及左侧小脑</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >地西泮 + 米诺环素</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >11.2</td><td align="center" valign="middle" >126</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >II型，累及双侧脑室周围白质</td><td align="center" valign="middle" >1 m</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >头孢呋辛</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >II型，累及双侧枕顶叶</td><td align="center" valign="middle" >4 m</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >拉氧头孢 + 酮康唑</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >多灶性棘波、尖波，睡眠时明显增加</td><td align="center" valign="middle" >头孢哌酮，苯巴比妥</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >121</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >补液</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1.95</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >134</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >1 m</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >抗生素(未具体说明)</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >9.4</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >氨苄青霉素 + 头孢曲松</td><td align="center" valign="middle" >PR</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >7 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >支持性液体补液疗法</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >2.8</td><td align="center" valign="middle" >24.4</td><td align="center" valign="middle" >130</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >II型，累及双侧白质</td><td align="center" valign="middle" >9 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >甲强龙，地塞米松 + 环孢素 + 依托泊苷</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >II型，累及双侧额顶叶白质</td><td align="center" valign="middle" >10 d</td><td align="center" valign="middle" >过度换气后可见中、高振幅(3~5 Hz)慢波，蝶骨电极左侧附近偶见尖波</td><td align="center" valign="middle" >未于医院接受治疗</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >23.1</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >12 d</td><td align="center" valign="middle" >后头部区域慢波</td><td align="center" valign="middle" >地塞米松；急诊内镜手术 + 哌拉西林他唑巴坦 + 美罗培南 + IVIG</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" >128</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >15 d</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >阿昔洛韦 + 万古霉，头孢噻肟</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >26</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >210.5</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >升高</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >11 d</td><td align="center" valign="middle" >弥漫性高电压慢波</td><td align="center" valign="middle" >甲强龙、IVIG，哌拉西林他唑巴坦、头孢唑林</td><td align="center" valign="middle" >CR</td></tr><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >NE</td><td align="center" valign="middle" >123</td><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >I型</td><td align="center" valign="middle" >18 d</td><td align="center" valign="middle" >左侧额颞叶慢波</td><td align="center" valign="middle" >头孢曲松 + 阿昔洛韦 + 甲强龙</td><td align="center" valign="middle" >CR</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 27例儿童RESLES的辅助检查及治疗预后情况</p><p>NE，未报告；d，天；m，月；IVIG，静注人免疫球蛋白；CR，临床完全康复；PR，临床部分康复。</p><p>27例中有18例为RESLES-I型(66.7%，18/27)，I型与II型的比例为2:1。1例未明确报告复查时间，其余26例复查MRI病变消失的时间与首次完善MRI时间的间隔为2天至4月，平均为22.3天。共有16例完善了脑电图检查，其中6例正常(37.5%，6/16)，10例异常(62.5%，10/16)，表现为慢波或(和)尖/棘波。</p><p>治疗上，除针对病原菌抗感染、抗病毒或抗真菌治疗外，1例使用左乙拉西坦抗癫痫，2例使用丙种球蛋白治疗，5例使用激素治疗(甲强龙/地塞米松/醋酸泼尼松)，4例联合使用可丙种球蛋白及激素治疗。其中有1例(病例24)在激素治疗过程中出现严重不良反应(胃肠道溃疡穿孔)而进行了急诊内镜手术。27例中预后良好且无后遗症者25例(92.6%，25/27)，未报告预后情况1例，有后遗症1例，表现为脑萎缩，伴有运动功能暂时性退化表现，但随时间推移有所改善(病例20)，见表2。</p></sec><sec id="s8"><title>4. 讨论</title><p>RESLES在儿童中报道较多，但近年来成人报道逐渐增多，就近五年的文献报道来看，成人有83篇，儿童仅22篇，病例分布仍以亚洲为主，但RESLES在不同人种间的发生率是否存在差异，仍需要大量病例资料及试验等方法去证实。由于受到颅脑MRI影像检查的限制，关于RESLSE的发病率仍然不能确定。一项关于脑炎/脑病的研究发现，其患者中发生胼胝体病变比例少于6%，RESLES发生率小于1%，而在癫痫相关患者中，其发病率为0.7% [<xref ref-type="bibr" rid="hanspub.42349-ref5">5</xref>]。RESLES的病因复杂多样，大致包括以下几类：1) 感染因素：① 从病原学角度来看，病毒、细菌或特殊病原菌感染后部分患者MRI上出现了类似的可逆性胼胝体压部病变。张扬等人 [<xref ref-type="bibr" rid="hanspub.42349-ref6">6</xref>] 发现MERS常见病因是A型流感病毒感染，其次为肺炎支原体、轮状病毒及腺病毒感染，少见病因为肠杆菌、EB病毒、新型隐球菌、猪流感病毒、肺炎双球菌等感染。此外，文献报道了COVID-19 [<xref ref-type="bibr" rid="hanspub.42349-ref7">7</xref>]、伤寒沙门氏菌 [<xref ref-type="bibr" rid="hanspub.42349-ref8">8</xref>] 等。② 从基础疾病的角度来看，胼胝体压部可逆性病变在大叶性肺炎 [<xref ref-type="bibr" rid="hanspub.42349-ref9">9</xref>]、急性肾盂肾炎 [<xref ref-type="bibr" rid="hanspub.42349-ref10">10</xref>] 等疾病中皆有报道。2) 非感染因素：除外感染相关疾病，RESLES在抗NMDAR脑炎 [<xref ref-type="bibr" rid="hanspub.42349-ref11">11</xref>]、系统性红斑狼疮 [<xref ref-type="bibr" rid="hanspub.42349-ref12">12</xref>] 等免疫相关疾病中亦有报道。此外，流行性腮腺炎疫苗接种后 [<xref ref-type="bibr" rid="hanspub.42349-ref13">13</xref>] 等诊疗过程中也发现了胼胝体压部在影像学上类似的表现。</p><p>RESLES的临床症状没有特异性，多与其病因相关，大部分病例表现为神经系统症状，呈脑炎/脑病表现多见。一般来说，成年人的常见神经表现是头痛和意识障碍。然而，意识障碍和惊厥发作则是儿童中最常见的神经症状 [<xref ref-type="bibr" rid="hanspub.42349-ref14">14</xref>]，推测这可能与儿童未成熟的中枢神经系统和血脑屏障有关。其他较少见的神经系统症状包括精神行为异常、视觉障碍(如幻视、视物模糊等)、构音障碍、共济失调、吞咽困难、急性尿潴留、腹泻等，且部分患者在最初在神经症状出现之前有其他感冒症状，如发热、咳嗽、咽痛、鼻塞和肌痛 [<xref ref-type="bibr" rid="hanspub.42349-ref6">6</xref>]。</p><p>RESLES目前没有特异性治疗方式，其治疗方案的选择与病因相关，需针对病因选择相应的治疗策略，一般RESLES预后良好，仅有少数存在后遗症，本文27例患儿中仅1例有后遗症表现，有脑萎缩，伴有运动功能暂时性退化表现，但症状随时间推移有所改善。</p></sec><sec id="s9"><title>5. 结论</title><p>胼胝体是连接左右大脑半球最大的脑白质结构，在信息整合中发挥重要作用。多种病变可累及胼胝体，而可逆性胼胝体压部病变综合征是其中比较特殊的一类疾病，具有典型的影像表现及临床特点，目前发病机制尚不清楚，研究多以回顾性病例分析及个案报道为主，本文对通过文献回顾，总结分析了RESLES的影像学表现、病因、临床特点及预后等多方面进行总，从而指导临床医生在医疗过程中能尽早识别本疾病，正确判断预后，避免过度医疗。</p></sec><sec id="s10"><title>致谢</title><p>感谢程敏副教授对本文写作的指导以及重庆医科大学附属儿童医院国家医学中心为本研究提供资料信息。</p></sec><sec id="s11"><title>文章引用</title><p>刘兰昕,程 敏. 儿童可逆性胼胝体压部病变综合征的文献回顾Literature Review of Reversible Splenial Lesion Syndrome in Children[J]. 临床医学进展, 2021, 11(05): 2147-2154. https://doi.org/10.12677/ACM.2021.115307</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42349-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.S., Chang, K.H., Kim, S.T., et al. (1999) Focal Lesion in the Splenium of the Corpus Callosum in Epileptic Patients: Antiepileptic Drug Toxicity? American Journal of Neuroradiology, 20, 125-129.</mixed-citation></ref><ref id="hanspub.42349-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tada, H., Takanashi, J., Barkovich, A.J., et al. (2004) Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion. Neurology, 63. &lt;br&gt;https://doi.org/10.1212/01.WNL.0000144274.12174.CB</mixed-citation></ref><ref id="hanspub.42349-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Garcia Monco, J.C., Cortina, I.E., Ferreira, E., et al. (2011) Reversible Splenial Lesion Syndrome (RESLES): What’s in a Name? Journal of Neuroimaging, 21, e1-e14. &lt;br&gt;https://doi.org/10.1111/j.1552-6569.2008.00279.x</mixed-citation></ref><ref id="hanspub.42349-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Liu, H., Yang, S., et al. (2016) Reversible Splenial Lesion Syndrome in Children: Retrospective Study and Summary of Case Series. Brain and Development, 38, 915-927. &lt;br&gt;https://doi.org/10.1016/j.braindev.2016.04.011</mixed-citation></ref><ref id="hanspub.42349-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, S., Ma, Y. and Feng, J. (2015) Clinicoradiological Spectrum of Reversible Splenial Lesion Syndrome (RESLES) in Adults. Medicine, 94, e512. &lt;br&gt;https://doi.org/10.1097/MD.0000000000000512</mixed-citation></ref><ref id="hanspub.42349-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">张扬, 陈为安, 毕涌, 等. 107例伴有胼胝体压部可逆性病灶的临床症状轻微的脑炎/脑病临床分析[J]. 中华全科医学, 2014, 12(6): 875-878.</mixed-citation></ref><ref id="hanspub.42349-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Aoud, S.E., Sorial, D., Selmaoui, A., et al. (2020) A First Case of Mild Encephalitis with Reversible Splenial Lesion (MERS) as a Presenting Feature of SARS-CoV-2. Revue Neurologique, 177, 139-141.</mixed-citation></ref><ref id="hanspub.42349-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Mckenzie, E.D., Sugarman, J., Peng, J., et al. (2020) Salmonella Typhi Bacteremia and Mild Encephalitis with a Reversible Splenial Lesion. Canadian Journal of Neurological Sciences, 47, 261-263.  
&lt;br&gt;https://doi.org/10.1017/cjn.2019.328</mixed-citation></ref><ref id="hanspub.42349-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, C., Wu, X., Qi, H., et al. (2016) Reversible Splenial Lesion Syndrome Associated with Lobar Pneumonia. Medicine, 95, e4798. &lt;br&gt;https://doi.org/10.1097/MD.0000000000004798</mixed-citation></ref><ref id="hanspub.42349-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Miranda, J., Pereira, I., Nunes, J., et al. (2020) Mild Encephalopathy/Encephalitis with a Reversible Splenial Lesion Associated with Acute Pyelonephritis: A Case Report. Neurología (English Edition), 35, 530-534.  
&lt;br&gt;https://doi.org/10.1016/j.nrleng.2018.07.010</mixed-citation></ref><ref id="hanspub.42349-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kaminski, J.A. and Pruss, H. (2019) N-Methyl-D-Aspartate Receptor Encephalitis with a Reversible Spleniallesion. European Journal of Neurology, 26, e68-e69. &lt;br&gt;https://doi.org/10.1111/ene.13900</mixed-citation></ref><ref id="hanspub.42349-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ohkubo, N., Nakano, K., Miyagawa, I., et al. (2020) Mild Encephalitis/Encephalopathy with Reversible Splenial Lesions in SLE. Internal Medicine, 59, 2439-2440. &lt;br&gt;https://doi.org/10.2169/internalmedicine.4612-20</mixed-citation></ref><ref id="hanspub.42349-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Takanashi, J., Shiihara, T., Hasegawa, T., et al. (2015) Clinically Mild Encephalitis with a Reversible Splenial Lesion (MERS) after Mumps Vaccination. Journal of the Neurological Sciences, 349, 226-228.  
&lt;br&gt;https://doi.org/10.1016/j.jns.2014.12.019</mixed-citation></ref><ref id="hanspub.42349-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, J., Yang, S., Wang, S., et al. (2017) Mild Encephalitis/Encephalopathy with Reversible Splenial Lesion (MERS) in Adults—A Case Report and Literature Review. BMC Neurology, 17, Article ID: 103.  
&lt;br&gt;https://doi.org/10.1186/s12883-017-0875-5</mixed-citation></ref></ref-list></back></article>